CVE-2022-38351 is a high-severity privilege escalation vulnerability affecting Suprema BioStar 2 v2.8.16, allowing an authenticated attacker to gain System Administrator privileges. The vulnerability has a CVSS score of 8.8, indicating a high impact on confidentiality, integrity, and availability, and can be exploited remotely with low attack complexity. Despite its severity, there is currently no public exploit code available (Metasploit, Nuclei, ExploitDB), and it is not listed on CISA's KEV catalog, suggesting no active exploitation. Community discussion and media coverage for this CVE are minimal.
| Vendor | Product | Version(s) | CPE |
|---|---|---|---|
2.8.16CPE matchmatch criteria | cpe:2.3:a:supremainc:biostar_2:2.8.16:*:*:*:*:*:*:* |
CVSS version used by this source: 3.1
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
The average CVE in this peer group has 0.0 Twitter, 0.0 Reddit, 0.3 Bluesky, 0.1 Mastodon, and 0.2 GitHub mentions.
No media coverage found for this CVE.
The average CVE in this peer group has 0.1 InfoSec Media, 0.0 Vendor Blog, and 0.0 Security Researcher mentions.
Remediation records are not available for this CVE.